External Advisory Board
The Ginny L. Clements Breast Cancer Research Institute External Advisory Board provides guidance to the Institute's leadership in order to encourage continuing organizational improvement in building a sound infrastructure to meet the needs of the Cancer Center's catchment area and the goals of its strategic plan. The Institute's advisory board is comprised of respected national leaders in the field of cancer research, oncology, and patient advocacy.
Anne Marie Mercurio
Anne Marie Mercurio is a patient research advocate primarily in oncology, who helps empower patients to be partners with their doctors and encourage disruptive innovation in areas of cancer research. She aspires to see that “meaningful change” is the end result of all efforts and not simply a buzzword or a catch-phrase.
Patricia LoRusso, DO
Dr. LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.
Carlos Arteaga, MD
Dr. Arteaga is an internationally recognized expert in breast cancer with more than 350 publications in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer.
Laura J. van ‘t Veer, PhD
Dr. van ‘t Veer is a world-renowned Molecular Biologist, and Leader of the Breast Oncology Program and Associate Director Applied Genomics at the UCFS Helen Diller Family Comprehensive Cancer Center. She’s also the former Head of Diagnostic Oncology of the Netherlands Cancer Institute, and inventor of MammaPrint. Her research focuses on personalized medicine.
Barbara A. Pockaj, MD
Barbara A. Pockaj, MD, is a surgical oncologist with a strong clinical and research interest in breast cancer and malignant melanoma. Dr. Pockaj’s research focuses not only on clinical studies but also translational science.